BIOMIRA REPORTS LUNG CANCER DRUG STUDY RESULTS

April 28, 2006

Biomira has reported results from a clinical trial of its non-small cell lung cancer drug, Stimuvax.

The final survival results from an analysis of the Phase IIb data confirmed a median survival in patients with Stage IIIB cancer of 30.6 months with Stimuvax, while patients in the same stage who were in a control test group had a median survival of 13.3 months.

KEYWORDS Drug Pipeline Alert

FDA Provides Update on Haimen Shengbang Laboratory’s Recall of Its Viral Transport Media Containers

BIOMIRA REPORTS LUNG CANCER DRUG STUDY RESULTS

Upcoming Events

Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

Building a World-Class Pharmaceutical Advertising and Promotion Review Program

The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

1st Annual Quality Management vSummit

Featured Products

FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

MicroPort Navibot Receives 510(k) Clearance for Its SkyWalker System

FDA Expands Approval of Pfizer and Myovant’s Myfembree to Include Endometriosis

FDA Provides Update on Haimen Shengbang Laboratory’s Recall of Its Viral Transport Media Containers

FDA Issues EUA for Monkeypox Vaccine

The Revised ICH E8: A Guide to New Clinical Trial Requirements